Weller M - Search Results

1

SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo.

Roth P, Kissel M, Herrmann C, Eisele G, Leban J, Weller M, Schmidt F. Roth P, et al. Among authors: weller m. Clin Cancer Res. 2009 Nov 1;15(21):6609-18. doi: 10.1158/1078-0432.CCR-09-0548. Epub 2009 Oct 13. Clin Cancer Res. 2009. PMID: 19825946 Free article.

2

Topotecan-based combination chemotherapy for human malignant glioma.

Schmidt F, Schuster M, Streffer J, Schabet M, Weller M. Schmidt F, et al. Among authors: weller m. Anticancer Res. 1999 Mar-Apr;19(2A):1217-21. Anticancer Res. 1999. PMID: 10368678

3

Human malignant glioma cell lines are refractory to retinoic acid-mediated differentiation and sensitization to apoptosis.

Schmidt F, Groscurth P, Dichgans J, Weller M. Schmidt F, et al. Among authors: weller m. Cell Physiol Biochem. 2000;10(3):159-68. doi: 10.1159/000016346. Cell Physiol Biochem. 2000. PMID: 10878446

4

Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release.

Wagenknecht B, Hermisson M, Groscurth P, Liston P, Krammer PH, Weller M. Wagenknecht B, et al. Among authors: weller m. J Neurochem. 2000 Dec;75(6):2288-97. doi: 10.1046/j.1471-4159.2000.0752288.x. J Neurochem. 2000. PMID: 11080180 Free article.

5

Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage.

Schmidt F, Rieger J, Wischhusen J, Naumann U, Weller M. Schmidt F, et al. Among authors: weller m. Eur J Pharmacol. 2001 Jan 19;412(1):21-5. doi: 10.1016/s0014-2999(00)00923-7. Eur J Pharmacol. 2001. PMID: 11166732

6

Treosulfan chemotherapy for recurrent malignant glioma.

Schmidt F, Wick W, Herrlinger U, Dichgans J, Weller M. Schmidt F, et al. Among authors: weller m. J Neurooncol. 2000 Sep;49(3):231-4. doi: 10.1023/a:1006496831144. J Neurooncol. 2000. PMID: 11212902 Clinical Trial.

7

Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma.

Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W. Wild-Bode C, et al. Among authors: weller m. Cancer Res. 2001 Mar 15;61(6):2744-50. Cancer Res. 2001. PMID: 11289157

8

Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.

Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bähr M, Ohgaki H, Ashkenazi A, Weller M. Roth W, et al. Among authors: weller m. Cancer Res. 2001 Mar 15;61(6):2759-65. Cancer Res. 2001. PMID: 11289159

9

Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells.

Schmidt F, Groscurth P, Kermer M, Dichgans J, Weller M. Schmidt F, et al. Among authors: weller m. Acta Neuropathol. 2001 Mar;101(3):217-24. doi: 10.1007/s004010000254. Acta Neuropathol. 2001. PMID: 11307620

10

N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells.

Platten M, Wild-Bode C, Wick W, Leitlein J, Dichgans J, Weller M. Platten M, et al. Among authors: weller m. Int J Cancer. 2001 Jul 1;93(1):53-61. doi: 10.1002/ijc.1289. Int J Cancer. 2001. PMID: 11391621

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,716 results

Search Page

Filters